Patents by Inventor Alexander O. Mujica

Alexander O. Mujica has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11910787
    Abstract: Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: February 27, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lisa Purcell, Alexander O. Mujica, Yajun Tang
  • Publication number: 20230345919
    Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.
    Type: Application
    Filed: May 19, 2023
    Publication date: November 2, 2023
    Inventors: Alexander O. Mujica, Viktoria Gusarova, Cheng Wang, Christos Kyratsous, Terra Potocky, Katherine Cygnar, Joel H. Martin
  • Patent number: 11696572
    Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: July 11, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Viktoria Gusarova, Cheng Wang, Christos Kyratsous, Terra Potocky, Katherine Cygnar, Joel H. Martin
  • Patent number: 11684050
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals, in some embodiments, comprise a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: June 27, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Elena Burova, Alexander O. Mujica, Ka-Man Venus Lai, Andrew J. Murphy
  • Publication number: 20230172172
    Abstract: This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36?, ? and ? ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.
    Type: Application
    Filed: January 25, 2023
    Publication date: June 8, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Alexander O. Mujica, Ka-Man Venus Lai, Sokol Haxhinasto, Zaruhi Hovhannisyan
  • Patent number: 11589562
    Abstract: This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36?, ? and ? ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: February 28, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Alexander O. Mujica, Ka-Man Venus Lai, Sokol Haxhinasto
  • Publication number: 20220361464
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 17, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Yajun Tang, Jeffrey D. Lee, Min Gao, Susan D. Croll, Lynn Macdonald, Ying Hu, Carmelo Romano
  • Patent number: 11419318
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: August 23, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Yajun Tang, Jeffrey D. Lee, Min Gao, Susan D. Croll, Lynn Macdonald, Ying Hu, Carmelo Romano
  • Publication number: 20210360908
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
  • Publication number: 20210301301
    Abstract: Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. Compositions and methods are provided which comprise a genetically modified rat or rat cell comprising a targeted genetic modification in the rat interleukin-2 receptor gamma locus, the rat ApoE locus, the rat Rag2 locus, the rat Rag1 locus and/or the rat Rag2/Rag1 locus. The various methods and compositions provided herein allows for these modified loci to be transmitted through the germline.
    Type: Application
    Filed: March 9, 2021
    Publication date: September 30, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jeffrey D. Lee, Alexander O. Mujica, Wojtek Auerbach, Ka-Man Venus Lai, David M. Valenzuela, George D. Yancopoulos
  • Patent number: 11102961
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: August 31, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
  • Patent number: 10975390
    Abstract: Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. Compositions and methods are provided which comprise a genetically modified rat or rat cell comprising a targeted genetic modification in the rat interleukin-2 receptor gamma locus, the rat ApoE locus, the rat Rag2 locus, the rat Rag1 locus and/or the rat Rag2/Rag1 locus. The various methods and compositions provided herein allows for these modified loci to be transmitted through the germline.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: April 13, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jeffrey D. Lee, Alexander O. Mujica, Wojtek Auerbach, Ka-Man Venus Lai, David M. Valenzuela, George D. Yancopoulos
  • Publication number: 20210068377
    Abstract: Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 11, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Lisa Purcell, Alexander O. Mujica, Yajun Tang
  • Patent number: 10863729
    Abstract: Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: December 15, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lisa Purcell, Alexander O. Mujica, Yajun Tang
  • Publication number: 20200370054
    Abstract: A non-human animal (e.g., a rodent) model for diseases associated with a C9ORF72 heterologous hexanucleotide repeat expansion sequence is provided, which non-human animal comprises a heterologous hexanucleotide repeat (GGGGCC) in an endogenous C9ORF72 locus. A non-human animal disclosed herein comprising a heterologous hexanucleotide repeat expansion sequence comprising at least one instance, e.g., repeat, of a hexanucleotide (GGGGCC) sequence may further exhibit a characteristic and/or phenotype associated with one or more neurodegenerative disorders (e.g., amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD), etc.). Methods of identifying therapeutic candidates that may be used to prevent, delay or treat one or more neurodegenerative (e.g., amyotrophic lateral sclerosis (ALS, also referred to as Lou Gehrig's disease) and frontotemporal dementia (FTD)) are also provided.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 26, 2020
    Inventors: David Heslin, Roxanne Ally, Chia-Jen Siao, Ka-Man Venus Lai, David M. Valenzuela, Chunguang Guo, Michael LaCroix-Fralish, Lynn Macdonald, Aarti Sharma-Kanning, Daisuke Kajimura, Gustavo Droguett, David Frendewey, Alexander O. Mujica
  • Patent number: 10781453
    Abstract: A non-human animal (e.g., a rodent) model for diseases associated with a C9ORF72 heterologous hexanucleotide repeat expansion sequence is provided, which non-human animal comprises a heterologous hexanucleotide repeat (GGGGCC) in an endogenous C9ORF72 locus. A non-human animal disclosed herein comprising a heterologous hexanucleotide repeat expansion sequence comprising at least one instance, e.g., repeat, of a hexanucleotide (GGGGCC) sequence may further exhibit a characteristic and/or phenotype associated with one or more neurodegenerative disorders (e.g., amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD), etc.). Methods of identifying therapeutic candidates that may be used to prevent, delay or treat one or more neurodegenerative (e.g., amyotrophic lateral sclerosis (ALS, also referred to as Lou Gehrig's disease) and frontotemporal dementia (FTD)) are also provided.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 22, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Heslin, Roxanne Ally, Chia-Jen Siao, Ka-Man Venus Lai, David M. Valenzuela, Aarti Sharma-Kanning, Daisuke Kajimura, Gustavo Droguett, David Frendewey, Alexander O. Mujica
  • Publication number: 20200154684
    Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.
    Type: Application
    Filed: June 27, 2018
    Publication date: May 21, 2020
    Inventors: Alexander O. Mujica, Viktoria Gusarova, Cheng Wang, Christos Kyratsous, Terra Potocky, Katherine Cygnar, Joel Martin
  • Publication number: 20200053992
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: November 4, 2019
    Publication date: February 20, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Elena Burova, Alexander O. Mujica, Ka-Man Venus Lai, Andrew J. Murphy
  • Publication number: 20200015462
    Abstract: This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36?, ? and ? ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.
    Type: Application
    Filed: July 16, 2019
    Publication date: January 16, 2020
    Inventors: Andrew J. Murphy, Alexander O. Mujica, Ka-Man Venus Lai, Sokol Haxhinasto, Zaruhi Hovhannisyan
  • Publication number: 20190320632
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: April 18, 2019
    Publication date: October 24, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy